Article Text

Download PDFPDF
Original research
Cognitive reserve in amyotrophic lateral sclerosis (ALS): a population-based longitudinal study
  1. Emmet Costello1,2,
  2. James Rooney3,4,
  3. Marta Pinto-Grau1,2,
  4. Tom Burke1,2,
  5. Marwa Elamin2,
  6. Peter Bede2,
  7. Roisin McMackin2,
  8. Stefan Dukic2,5,
  9. Alice Vajda2,
  10. Mark Heverin2,
  11. Orla Hardiman2,
  12. Niall Pender1,2
  1. 1Department of Psychology, Beaumont Hospital, Dublin 9, Ireland
  2. 2Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Dublin 2, Ireland
  3. 3Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
  4. 4Institute and Clinic for Occupational, Social- and Environmental Medicine, University Hospital, Munich, Germany
  5. 5Department of Neurology, University Medical Centre Utrecht Brain Centre, Utrecht, The Netherlands
  1. Correspondence to Emmet Costello, Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Dublin D02 R590, Ireland; ecostel2{at}tcd.ie

Abstract

Background Amyotrophic lateral sclerosis (ALS) is often associated with cognitive and/or behavioural impairment. Cognitive reserve (CR) may play a protective role in offsetting cognitive impairment. This study examined the relationship between CR and longitudinal change in cognition in an Irish ALS cohort.

Methods Longitudinal neuropsychological assessment was carried out on 189 patients over 16 months using the Edinburgh cognitive and behavioural ALS screen (ECAS) and an additional battery of neuropsychological tests. CR was measured by combining education, occupation and physical activity data. Joint longitudinal and time-to-event models were fitted to investigate the associations between CR, performance at baseline and decline over time while controlling for non-random drop-out.

Results CR was a significant predictor of baseline neuropsychological performance, with high CR patients performing better than those with medium or low CR. Better cognitive performance in high CR individuals was maintained longitudinally for ECAS, social cognition, executive functioning and confrontational naming. Patients displayed little cognitive decline over the course of the study, despite controlling for non-random drop-out.

Conclusions These findings suggest that CR plays a role in the presentation of cognitive impairment at diagnosis but is not protective against cognitive decline. However, further research is needed to examine the interaction between CR and other objective correlates of cognitive impairment in ALS.

Statistics from Altmetric.com

Footnotes

  • Twitter @EmmetCostello, @@jpkrooney, @RoisinTCDNeuro, @@PenderNiall

  • Contributors EC, OH and NP designed and conceptualised the study. EC, JR, MP-G, TB, ME, PB, MH and AV played a major role in the acquisition of data. EC and JR analysed and interpreted the data. EC drafted the manuscript for intellectual content. EC, JR, MP-G, TB, ME, RM, SD, PB, MH, OH and NP revised the manuscript for intellectual content.

  • Funding This research has received funding from Science Foundation Ireland (SFI), grant 16/ERCD/3854, grant number 205532, the European Community's Seventh Framework Programme (FP7/2007-2013) under the Health Cooperation programme and the project EUROMOTOR (no 259867), and the Charities Research Motor Neurone (no grant number) and Irish Motor Neurone Disease Association (no grant number). Peter Bede is supported by the Health Research Board (HRB EIA-2017-019), the EU Joint Programme–Neurodegenerative Disease Research (JPND-2017-1), the Andrew Lydon scholarship (No grant number), and the Iris O'Brien Foundation (no grant number). JR is supported by the European Union Marie Skłodowska-Curie Action (no 846794).

  • Competing interests NP serves as Associate Editor of the International Journal of Neuroscience and has received speaker honoraria from Novartis. OH has received speaking honoraria from Janssen Cilag, Biogen Idec, Sanofi Aventis, Novartis and MerckSerono. She has been a member of advisory panels for Biogen Idec, Allergen, Ono Pharmaceuticals, Novartis, Cytokinetics and Sanofi Aventis. She serves as editor-in-chief of the journal Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

  • Patient consent for publication Not required.

  • Ethics approval Ethical approval was granted by Beaumont Hospital ethics committee (ID: REC Ref- 06/79 and REC Ref- 13/102).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Anonymised data are available on reasonable request.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.